PMID- 26240207
OWN - NLM
STAT- MEDLINE
DCOM- 20151230
LR  - 20150924
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 136
IP  - 3
DP  - 2015 Sep
TI  - Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal 
      and Tdap Vaccines.
PG  - e563-72
LID - 10.1542/peds.2014-4199 [doi]
AB  - BACKGROUND: This study in 11- to 15-year-old boys and girls compared the 
      immunogenicity and safety of GARDASIL 9 (9-valent human papillomavirus [9vHPV] 
      vaccine) administered either concomitantly or nonconcomitantly with 2 vaccines 
      routinely administered in this age group (Menactra [MCV4; Neisseria meningitidis 
      serotypes A/C/Y/W-135] or Adacel [Tdap; diphtheria/tetanus/acellular pertussis]). 
      METHODS: Participants received 9vHPV vaccine at day 1 and months 2 and 6; the 
      concomitant group (n = 621) received MCV4/Tdap concomitantly with 9vHPV vaccine 
      at day 1; the nonconcomitant group (n = 620) received MCV4/Tdap at month 1. 
      Antibodies to HPV-, MCV4-, and Tdap-relevant antigens were determined. 
      Injection-site and systemic adverse events (AEs) were monitored for 15 days after 
      any vaccination; serious AEs were monitored throughout the study. RESULTS: The 
      geometric mean titers for all HPV types in 9vHPV vaccine 4 weeks after dose 3, 
      proportion of subjects with a fourfold rise or greater in titers for 4 N 
      meningitidis serotypes 4 weeks after injection with MCV4, proportion of subjects 
      with antibody titers to diphtheria and tetanus >/=0.1 IU/mL, and geometric mean 
      titers for pertussis antigens 4 weeks after injection with Tdap were all 
      noninferior in the concomitant group compared with the nonconcomitant group. 
      Injection-site swelling occurred more frequently in the concomitant group. There 
      were no vaccine-related serious AEs. CONCLUSIONS: Concomitant administration of 
      9vHPV vaccine with MCV4/Tdap was generally well tolerated and did not interfere 
      with the antibody response to any of these vaccines. This strategy would minimize 
      the number of visits required to deliver each vaccine individually.
CI  - Copyright (c) 2015 by the American Academy of Pediatrics.
FAU - Schilling, Andrea
AU  - Schilling A
AD  - Facultad de Medicina Clinica Alemana-Universidad del Desarrollo, Santiago, Chile; 
      dra.andrea.schilling@gmail.com.
FAU - Parra, Mercedes Macias
AU  - Parra MM
AD  - Instituto Nacional de Pediatria, Mexico City, Mexico;
FAU - Gutierrez, Maricruz
AU  - Gutierrez M
AD  - Hospital del Nino Poblano, Puebla, Mexico;
FAU - Restrepo, Jaime
AU  - Restrepo J
AD  - Fundacion Centro de Investigacion Clinica CIC, Medellin, Colombia;
FAU - Ucros, Santiago
AU  - Ucros S
AD  - Centro de Investigaciones en Salud, Fundacion Santa Fe de Bogota, Bogota, 
      Colombia;
FAU - Herrera, Teobaldo
AU  - Herrera T
AD  - Insituto de Investigacion Nutricional anexo Huascar, Lima, Peru;
FAU - Engel, Eli
AU  - Engel E
AD  - Bayview Research Group, Valley Village, California;
FAU - Huicho, Luis
AU  - Huicho L
AD  - Instituto Nacional de Salud del Nino, Lima, Peru;
FAU - Shew, Marcia
AU  - Shew M
AD  - Indiana University School of Medicine/Department of Pediatrics, Indianapolis, 
      Indiana; and.
FAU - Maansson, Roger
AU  - Maansson R
AD  - Merck & Co., Inc., Kenilworth, New Jersey.
FAU - Caldwell, Nicole
AU  - Caldwell N
AD  - Merck & Co., Inc., Kenilworth, New Jersey.
FAU - Luxembourg, Alain
AU  - Luxembourg A
AD  - Merck & Co., Inc., Kenilworth, New Jersey.
FAU - Ter Meulen, Ajoke Sobanjo
AU  - Ter Meulen AS
AD  - Merck & Co., Inc., Kenilworth, New Jersey.
LA  - eng
SI  - ClinicalTrials.gov/NCT00988884
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150803
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 0 (Diphtheria-Tetanus-Pertussis Vaccine)
RN  - 0 (Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18)
RN  - 0 (Meningococcal Vaccines)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Diphtheria-Tetanus-Pertussis Vaccine/*administration & dosage
MH  - Female
MH  - Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 
      18/*administration & dosage
MH  - Humans
MH  - *Immunization Schedule
MH  - Male
MH  - Meningococcal Vaccines/*administration & dosage
MH  - United States
MH  - Vaccination/*methods
EDAT- 2015/08/05 06:00
MHDA- 2015/12/31 06:00
CRDT- 2015/08/05 06:00
PHST- 2015/06/11 00:00 [accepted]
PHST- 2015/08/05 06:00 [entrez]
PHST- 2015/08/05 06:00 [pubmed]
PHST- 2015/12/31 06:00 [medline]
AID - peds.2014-4199 [pii]
AID - 10.1542/peds.2014-4199 [doi]
PST - ppublish
SO  - Pediatrics. 2015 Sep;136(3):e563-72. doi: 10.1542/peds.2014-4199. Epub 2015 Aug 
      3.